Cite
HARVARD Citation
Tree, A. et al. (2022). Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet oncology. 23 (10), pp. 1308-1320. [Online].